Drug intelligence / Profile preview

ro 16-6491

Development stage: Discontinued
Lead developer: Roche
Modality: Small Molecules
Administration: In Vitro (experimental Use), Not Used In Humans Clinically

Overview

RO16-6491 is a **reversible inhibitor of monoamine oxidase type B (MAO-B)**, primarily used in research contexts. It binds specifically and with high affinity to MAO-B in tissues such as human brain mitochondria and platelet membranes. RO16-6491 shows weak inhibition of amine uptake at relatively high concentrations and is distinguished from irreversible MAO-B inhibitors by its reversible binding. The compound has also been used as a radioligand probe for mapping MAO-B distribution in tissues[1][3][5].

Other names: N-(2-Aminoethyl)-4-chlorobenzamide hydrochloride

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on ro 16-6491.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ro 16-6491.

Explore the full profile